All articles tagged with #eloratzp
Eli Lilly reported that its experimental triple-agonist retatrutide caused an average weight loss of 49.6 pounds in patients with Type 2 diabetes, while a new combination therapy, EloraTZP, achieved up to 54.1 pounds of loss. Both drugs target multiple gut hormones to enhance satiety and metabolic control, with retatrutide expected to seek FDA approval by March 2027.
Eli Lilly reported that its experimental combination therapy, eloraTZP, achieved an average weight loss of 23.3% in patients with obesity and type 2 diabetes, surpassing its own triple-agonist candidate retatrutide in that specific population. The Phase 2 trial, presented at the European Association for the Study of Diabetes in Milan, showed that the highest dose of the amylin and tirzepatide combo resulted in a 54.1-pound loss over 48 weeks. While efficacy was strong, discontinuation rates due to gastrointestinal side effects were higher than for individual components. Lilly plans to begin Phase 3 trials in the fourth quarter of 2026, aiming to optimize dosing to improve tolerability while maintaining efficacy.
Eli Lilly presented detailed phase 3 data for retatrutide and phase 2 results for the experimental combination EloraTZP at the European Association for the Study of Diabetes in Milan. Retatrutide, a triple-agonist, achieved 20.8% average weight loss at the top dose, while EloraTZP, combining amylin and tirzepatide, reached 23.3% weight loss. Lilly plans to file for retatrutide approval in early 2027 and advance EloraTZP to phase 3 trials by year-end.